RxDoctor Payments Data

Yousef Sadiq, MD

Internal Medicine · Rialto, CANPI 1417067588

Payments from drug & device makers

$555in general payments, 2019–2025

Across 35 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$209
  • Lilly USA, LLC$67
  • Novartis$53
  • Amarin Pharma, Inc.$53
  • Boehringer Ingelheim$50
  • Abbott$34
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$555 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$22,054
Medicare patients
60
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban35$35,056
OzempicSemaglutide36$34,359
EliquisApixaban43$31,592
TrulicityDulaglutide18$30,990
JanuviaSitagliptin Phosphate34$27,447
JardianceEmpagliflozin21$22,677
EntrestoSacubitril/Valsartan15$18,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$18,196
TradjentaLinagliptin15$11,226
LinzessLinaclotide21$10,921
FarxigaDapagliflozin Propanediol13$10,443
MyrbetriqMirabegron20$10,236
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,783
Rosuvastatin Calcium249$5,360
Albuterol Sulfate HfaAlbuterol Sulfate130$5,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$50$33,90336 claims
PfizerEliquis$13$31,59243 claims
Lilly USA, LLCTrulicity$67$30,99018 claims
NovartisEntresto$53$18,43015 claims
Astellas Pharma US IncMyrbetriq$25$10,23620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rialto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →